Results 31 to 40 of about 4,490 (182)

Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer

Cell Reports, 2020
Summary: NTRK1 gene fusions are actionable drivers of numerous human malignancies. Here, we show that expression of the TPR-NTRK1 fusion kinase in immortalized mouse pancreatic ductal epithelial (IMPE) (pancreas) or mouse lung epithelial (MLE-12) cells ...
Aria Vaishnavi, Michael T. Scherzer, Conan G. Kinsey, Gennie L. Parkman, Amanda Truong, Phaedra Ghazi, Sophia Schuman, Benjamin Battistone, Ignacio Garrido-Laguna, Martin McMahon   +9 more
doaj   +1 more source

Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer [PDF]

, 2016
Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clinical testing in colorectal cancer and other tumor types. A patient with metastatic colorectal cancer harboring an LMNA-NTRK1 rearrangement displayed a remarkable response ...
Misale, Sandra, L. Novara, M. Russo, S. Siena, Rospo, Giuseppe, G. Crisafulli, R. Wild, R. Patel, A. Bartolini, Lazzari, Luca, Di Nicolantonio, Federica, G. Corti, S. Misale, Russo, Mariangela, S. Yan, N. Cam, G. Wei, F. Di Nicolantonio, R. Shoemaker, Siravegna, Giulia, A. Sartore Bianchi, L. Lazzari, G. Li, Crisafulli, Giovanni, B. Mussolin, Bardelli, Alberto, G. Rospo, G. Siravegna, A. Bardelli   +28 more
core   +1 more source

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib

Frontiers in Oncology, 2023
Pancreatic neuroendocrine carcinoma (panNEC) is a rare disease. The rearrangements of neurotrophic tropomyosin receptor kinase (NTRK) genes are oncogenic.
Wen-Chi Wu, Wen-Chi Wu, Wen-Chi Wu, Wen-Chi Wu, Ming-Huang Chen, Ming-Huang Chen, Ming-Huang Chen   +6 more
doaj   +1 more source

Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report

, 2022
Crizotinib and entrectinib are approved tyrosine kinase inhibitors by the FDA to treat advanced-stage ROS1-positive non-small cell lung cancer (NSCLC).
Saadettin Kılıçkap, Guven, Deniz Can, Kılıçkap, Saadettin, Taban, Hakan, Hakan Taban, Kilickap, Saadettin, Deniz Can Guven   +6 more
core   +1 more source

Development of Neuropathic Arthropathy With Entrectinib: Case Report

JTO Clinical and Research Reports, 2022
TRK inhibition can lead to on-target neurologic adverse events. Two cases illustrate the development of neuropathic arthropathy as a side effect of entrectinib.
Nicholas P. Giustini, MD, Hanna Oh, MD, Keith D. Eaton, MD, PhD   +2 more
doaj   +1 more source

Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer

Frontiers in Oncology, 2023
IntroductionExpression of the NTRK gene is rare in solid tumors but is highly prevalent in salivary gland secretory carcinomas. Here, we report a case of a complete response to entrectinib in a patient with NTRK fusion gene-positive parotid carcinoma ...
Etsuko Moriyama, Etsuko Moriyama, Sachiko Nagasu, Sachiko Nagasu, Toshimitsu Tanaka, Toshimitsu Tanaka, Yasutaka Shimotsuura, Yasutaka Shimotsuura, Takeharu Ono, Hirohito Umeno, Jun Akiba, Akihiko Kawahara, Fumihiko Fujita, Takumi Kawaguchi, Keisuke Miwa   +14 more
doaj   +1 more source

Cost-effectiveness analysis of treating patients with ntrk-positive cancer with the histology-independent therapy entrectinib [PDF]

, 2022
Objectives This study tackles several challenges of evaluating histology-independent treatments using entrectinib as an example. Histology-independent treatments are provided based on genetic marker(s) of tumors, regardless of the tumor type.
Vellekoop, Heleen, Rutten-van Mölken, Maureen, Nagy, Balázs, Versteegh, Matthijs, Rutten-van Mölken, Maureen; id_orcid, Santi, Irene, Szilberhorn, László, Zelei, Tamás, Wordsworth, Sarah, Huygens, Simone, Tsiachristas, Apostolos, Koleva-Kolarova, Rositsa   +11 more
core   +1 more source

TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report

Current Oncology, 2022
NTRK gene fusions are rare oncogenic driver mutations that can be found in a broad range of neoplasms. In secretory carcinoma (SC), ETV6-NTRK3 gene fusion is seen in a majority of the cases and represents a druggable target for patients with advanced ...
Matthew S. Ernst, John T. Lysack, Martin D. Hyrcza, Shamir P. Chandarana, Desiree Hao   +4 more
doaj   +1 more source

Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers [PDF]

, 2022
Information regarding the comparative efficacy of first‐generation receptor tyrosine kinase inhibitors is limited. This matching‐adjusted indirect comparison (MAIC) evaluated differences in efficacy and safety across larotrectinib and entrectinib trials.
Marian, Marisca, Jesus Garcia-Foncillas, Carsten Bokemeyer, García-Foncillas López, Jesús Miguel, Paracha, Noman, Fillbrunn, Mirko, Keating, Karen, Italiano, Antoine, Fellous, Marc, Gao, Wei, Marc Fellous, Garcia‐foncillas, Jesus, Antoine Italiano, Ayyagari, Rajeev, Karen Keating, Marisca Marian, Lassen, Ulrik, Noman Paracha, Bokemeyer, Carsten, Mirko Fillbrunn, Rajeev Ayyagari, Wei Gao, Ulrik Lassen   +22 more
core   +1 more source

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

Current Oncology, 2021
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao   +17 more
doaj   +1 more source